Table 1 Inclusion criteria according to the population–intervention–comparison–outcome (study design) model
Population | Patients with clinically significant BRVO or CRVO |
|---|---|
Intervention | 1. Ranibizumab |
2. Bevacizumab | |
3. Dexamethasone IVT | |
4. Laser photocoagulation | |
Comparison | Any of the interventions listed above and any of the following: |
1. Best supportive care | |
2. Grid pattern photocoagulation | |
3. Sham injections | |
4. Mixed treatment comparisons | |
Outcomes | Data for BRVO and CRVO were extracted separately where possible |
Primary measures (at least one of the following extracted for every study) | |
1. Mean change in BCVA from baseline | |
2. Number of patients gaining ≥ 10 letters from baseline to 6 months | |
Secondary measures extracted if available | |
1. Number of patients gaining ≥ 15 letters | |
2. AEs | |
3. SAEs | |
4. Vision-related quality of life | |
Study design | Randomized controlled trials of any publication date |